Dermatology

Janet A. Fairley, MD, FAAD

Portrait

Chair, John S. Strauss Professor and Head
Professor of Dermatology

Contact Information

Office: 40040 Pomerantz Family Pavilion
200 Hawkins Drive
Iowa City, IA 52242
Office Phone: 319-356-3609

Email: janet-fairley@uiowa.edu

Education

BS, Zoology, Michigan State University
MD, Medicine, University of Michigan Medical School

Internship, Hennepin County Medical Center, Minneapolis, MN
Residency, Dermatology, University of Michigan, Ann Arbor, MI
Fellowship, NIH Research, Cell Physiology, Dermatology, University of Michigan, Ann Arbor, MI

Licensure and Certifications

State of Iowa Medical License, Iowa Board of Medicine
State of Michigan Medical License, Michigan Board of Medicine
Board Certified, American Board of Dermatology
Board Certified, National Board of Medical Examiners

Education/Training Program Affiliations

Interdisciplinary Graduate Program in Translational Biomedicine

Research Summary

The overall goal of the current research in my laboratory is to better understand the pathogenesis of the organ-specific autoimmune blistering diseases, such as bullous pemphigoid. Bullous pemphigoid (BP) is an blistering skin disease skin characterized by development of autoantibodies against BP180, a cell-substrate attachment protein. Early studies of the pathogenesis of BP were focused on autoantibodies of the IgG class; however, findings from our work and others have made it clear that IgE class autoantibodies also play a critical role in this disease process. We have shown that 90% of BP patients produce IgE autoantibodies that target the same small antigenic region of BP180 (termed NC16A) that is recognized by IgG autoantibodies. Further, BP IgE, when passively transferred into a xenograft murine model, can replicate the early phase of BP lesion development. This was the first demonstration of the pathogenicity of human IgE in an autoimmune disease. Treatment of basophils isolated from BP patients with the NC16A peptide was shown to induce specific degranulation of the cells, suggesting one mechanism by which IgE may contribute to lesion development. Recently we have utilized our research on IgE for the basis of a clinical trials of anti-IgE therapy in BP. Our future goals are to further delineate the role of IgE autoantibodies and effectors cells such as eosinophils and mast cells in BP and to utilize this information to identify additional novel therapies for autoimmune diseases.

As a physician-scientist one of my major goals is to translate findings from the laboratory into improved diagnostics and or therapies for patients.

All Publications

Yu L, Crew A, Messingham K, Fairley J, Woodley D.  Omalizumab therapy for bullous pemphigoid.  J Am Acad Dermatol.  2014 June 20. 
[PubMed]

Kelchen M, Holdren G, Farley M, Zimmerman M, Fairley J, Brogden N.  Optimization of Impedance Spectroscopy Techniques for Measuring Cutaneous Micropore Formation after Microneedle Treatment in an Elderly Population.  Pharm Res.  2014 June 20. 
[PubMed]

Messingham K, Holahan H, Fairley J.  Unraveling the significance of IgE autoantibodies in organ-specific autoimmunity: lessons learned from bullous pemphigoid.  Immunol Res.  2014 May 21. 

Holahan H, Farah R, Selby J, Fairley J.  Erythema annulare-like acantholytic dermatosis: A subset of pemphigus folia.  Br J Dermatol.  2014 May 16. 
[PubMed]

Hall R, Streilein R, Hannah D, McNair P, Fairley J, Ronaghy A, Edhegard K, Levesque M.  Association of serum B-cell activating factor level and proportion of memory and transitional B cells with clinical response after rituximab treatment of bullous pemphigoid patients.  J Invest Dermatol.  2013 December. 133(12):2786-8.

Fairley J, Bream M, Fullenkamp C, Syrbu S, Chen M, Messingham K.  Missing the target: characterization of bullous pemphigoid patients who are negative using the BP180 enzyme-linked immunosorbant assay.  Jour Am Acad Derm.  2013 March. 68(3):395-403.
[PubMed]

Fairley J, Krueger G, Lessin S, Leyden J, McBurney E, Orlow S, Tharp M, Voorhees J, Wintroub B, Yancey K.  The Dermatology Foundation: partnerships and programs focused on the future.  Journal of Investigative Dermatology.  2013. 4(133):861-2.
[PubMed]

Wilson T, Legler A, Madison K, Fairley J, Swick B.  Erythema migrans: a spectrum of histopathologic changes.  AM J Dermatopath.  2012 December. 34(8):834-7.
[PubMed]

Messingham K, Pietras T, Fairley J.  Role of IgE in bullous pemphigoid: a review and rationale for IgE directed therapies.  G Ital Dermatol Venereol.  2012 June. 147(3):251-7.
[PubMed]

Fairley J.  Cutaneous mineralization and ossification.  McGraw Hill, New York, NY.  2012 March 20. 

Murrell D, Daniel B, Joly P, Borradori L, Amagai M, Hashimoto T, Caux F, Marinovic B, Sinha A, Hertl M, Bernard P, Sirois D, Cianchini G, Fairley J, Jonkman M, Pandya A, Rubenstein D, Zillikens D, Payne A, Woodley D, Zambruno G, Aoki V, Pincelli C, Diaz L, Hall R, Meurer M, Mascaro Jr J, Schmidt E, Shimizu H, Zone J, Swerlick R, Mimouni D, Culton D, Lipozencic J, Bince B, Grando S, Bystryn J, Werth V.  Definitions and outcome measures for bullous pemphigoid: recommendations by an international panel of experts.  J Am Acad Dermatol .  2012 March. 66(3):479-85.

Asarch A, Swick B, Fairley J.  Cryptic esophageal pemphigus vulgaris despite apparent clinical remission.  J Am Acad Dermatol.  2012. 67(5):e213-4.
[PubMed]

Messingham K, Frydman A, Roewe R, Fairley J.  FA role for IgE receptor expression on eosinophils in BP.  J Invest Derm.  2012. 132(4):S1-S18.

Messingham K, Frydman A, Roewe R, Fairley J.  FceRI expression by eosinophils in BP and a potential pathogenic role in eosinophil degranulation.  J Invest Dermatol.  2012. 132.

Messingham K, Vanderah E, Onoh A, Giudice G, Fairley J.  Functional characterization of an IgE-class monoclonal antibody specific for the bullous pemphigoid autoantigen, BP180.  2012. 31(2):111-7.
[PubMed]

Fairley J.  Monoclonal antibody BP180 against bullous pemphigoid antigen-2 type XVII collagen.  Hybridoma (Larchmt).  2012. 31(2):146-7.
[PubMed]

Hochwalt P, Asarch A, Stone M, Fairley J.  Numerous skin-colored papules on the face and neck.  2012. 148(7):849-54.
[PubMed]

London V, Kim G, Woodley D, Fairley J.  Successful treatment of bullous pemphigoid with omalizumab.  2012. 148(11):1241-3.
[PubMed]

Hall R, Fairley J, Woodley V, Werth V.  Treatment of patients with pemphigus vulgaris (PV) with infliximab and prednisone is associated with decreased autoantibodies and increase in immature B cells compared to treatment with prednisone.  J Invest Derm.  2012. 

Hall R, Fairley J, Woodley D, Werth V.  Treatment of patients with pemphigus vulgaris (PV) with infliximab and prednisone is associated with decreased autoantibodies and increase in immature B cells compared to treatment with prednisone.  J Invest Dermatol.  2012. 132.

Frydman A, Fairley J.  New and innovative interventions in the management of pemphigus.  2011 June. 146(3):211-24.
[PubMed]

Bassis A, Fairley J, Ameln R, Swick B.  Cutaneous Rosai-Dorfman disease following pneumococcal vaccination.  J Am Acad Dermatol .  2011. 65(4):890-2.
[PubMed]

Frydman A, Messingham K, Fairley J.  Eosinophils express the high affinity IgE receptor(FceRI) in bullous pemphigoid.  J Invest Dermatol.  2011. 131:S8 (043A).

Messingham K, Srikantha R, DeGueme A, Fairley J.  FcR-independent effects of IgE and IgG autoantibodies in bullous pemphigoid.  J Immunol .  2011. 187(1):553-60.
[PubMed]

Messingham K, Onoh A, Vanderah E, Giudice G, Fairley J.  An IgE monoclonal antibody to BP180-NC16A replicates the effects of bullous pemphigoid IgE in vitro.  J Invest Dermatol.  2010. 110:S9 (049A).

Swick B, Srikantha R, Messingham K, Fairley J.  Further characterization of C-KIT and PDGFR-alpha mutational status in Merkel cell carcinoma; Implications for treatment with imatinib mesylate.  J Invest Dermatol.  2010. 110:S31 (183A).

Noe M, Messingham K, Brandt D, Andrews J, Fairley J.  Pregnant women have increased incidence of IgE autoantibodies reactive with the skin and placental antigen BP180 (type XVII collagen).  J Reprod Immunol .  2010. 85(2):198-204.

Messingham K, Jay M, Fairley J.  Signal transduction triggered by IgE class autoantibodies in bullous pemphigoid.  J Invest Dermatol.  2010. 110:S19 (109A).

Messingham K, Noe M, Chapman M, Giudice G, Fairley J.  A novel ELISA reveals high frequencies of BP180-specific IgE production in bullous pemphigoid.  J Immunol Methods.  2009. 346(1-2):18-25.
[PubMed]

Wong M, Giudice G, Fairley J.  Autoimmunity in bullous pemphigoid.  G Ital Dermatol Venereol.  2009. 144(4):411-21.
[PubMed]

Messingham K, DeGueme A, Fairley J.  BP180-specific IgE directly affects keratinocyte structure and function.  J invest Dermatol.  2009. 129:S15 (89A).

Helmbach L, Li N, Huang W, Giudice G, Fairley J, Marinkovich P, Diaz L, Liu Z.  Mapping pathogenic epitopes recognized by herpes gestationis autoantibodies using humanized BP180NC16A mice.  J Invest Dermatol.  2009. 129:S17 (97A).

Fairley J, Baum C, Brandt D, Messingham K.  Pathogenicity of IgE in autoimmunity: successful treatment of bullous pemphigoid with omalizumab.  J Allergy Clin Immunol.  2009. 123(3):704-5.
[PubMed]

Noe M, Messingham K, Brandt D, Fairley J.  Pregnant women have an increased incidence of IgE-class antibodies directed against BP180.  J Invest Dermatol.  2009. 129:S15 (85A).

Wong M, Messingham K, Boddicker E, Arlian L, Yancey K, Fairley J.  The presence of cutaneous autoantibodies in scabies.  J Invest Dermatol.  2009. 129:S17 (98A).

Messingham K, Noe M, Chapman M, Giudice G, Fairley J.  Development of an ELISA to detect BP180-specific IgE.  J Invest Dermatol.  2008. 128:S24 (143A).

Noe M, Chen M, Woodley D, Fairley J.  Familial epidermolysis bullosa acquisita.  Dermatol Online J.  2008. 14(12):2.
[PubMed]

Lazarova Z, Salato V, Landschuetzer C, Janson M, Fairley J, Yancey K.  IgG anti-laminin-332 autoantibodies are present in a subset of patients with mucous membrane, but not bullous, pemphigoid.  J Am Acad Dermatol.  2008. 58(6):951-8.
[PubMed]

Liu Z, Sui W, Zhao M, Li Z, Li N, Thresher R, Giudice G, Fairley J, Sitaru C, Zillikens D, Ning G, Marinkovich M, Diaz L.  Subepidermal blistering induced by human autoantibodies to BP180 requires innate immune players in a humanized bullous pemphigoid mouse mod.  J Autoimmun.  2008. 31(4):331-8.
[PubMed]

Conlon J, Dauenhauer M, Tonkovic-Capin V, Talano J, Margolis D, Drolet B, Fairley J.  Voriconazole-induced blistering in the setting of graft versus host disease: A report of 2 patients.  J Am Acad Dermatol.  2008. 58(3):848-7.
[PubMed]

Fairley J, Burnett C, Fu C, Larson D, Fleming M, Giudice G.  A pathogenic role for IgE in autoimmunity: bullous pemphigoid IgE reproduces the early phase of lesion development in human skin grafted to nu/nu mice.  J Invest Dermatol.  2007. 127(11):2605-11.
[PubMed]

DeGueme A, Giudice G, Fu C, Fairley J.  Bullous pemphigoid IgE stimulates IL-8 production by keratinocytes.  J Invest Dermatol.  2007. 127:S17 (99A).

Liu Z, Leighty L, Zhao M, Li N, Fu C, Giudice G, Fairley J, Sitaru C, Zillikens D.  Identification of BP180 pathogenic epitope using humanized BP 180 NC16A mice.  J Invest Dermatol.  2007. 127:S12 (70A).

Chapman M, Olague-Marchan M, Yancey K, Giudice G, Fairley J.  IgE class autoantibodies against BP180 in herpes gestationis and cicatricial pemphigoid.  J Invest Dermatol.  2007. 127:S15 (90A).

Robbins A, Lazarova Z, Jansen M, Fairley J.  Pemphigus vulgaris presenting in a radiation portal.  J Am Acad Dermatol.  2007. 56(5 Supple):S82-5.
[PubMed]

Salato V, Lazarova Z, Janson M, Fairley J, Yancey K.  Bullous pemphigoid patients do not possess IgG autoantibodies reactive with lamnin 5.  J Invest Dermatol.  2006. 126:8A (47A).

Burnett C, Fu C, Janson M, Larson D, Giudice G, Fairley J.  Development of a model for testing the pathogenicity of BP IgE autoantibodies.  J Invest Dermatol.  2005. 124:A11 (061A).

Fairley J, Burnett C, Fu C, Fleming M, Giudice G.  Injection of bullous pemphigoid (BP) IgE autoantibodies into human skin grafted to nu/nu mice replicates the urticarial stage of BP.  J Invest Dermatol.  2005. 124:A13 (073A).

Fairley J, Fu C, Giudice G.  Mapping the binding sites of anti-BP180 immunoglobulin E autoantibodies in bullous pemphigoid.  J Invest Dermatol.  2005. 125:467-472.

Salato V, Lopez A, Lazarova Z, Fairley J, Lin M.  Monoclonal murine anti-idiotypic IgG blocks the development of experimental pemphigus vulgari.  J Invest Dermatol.  2005. 124:A6 (031A).

Salato V, Hacker-Foegen M, Lazarova Z, Fairley J, Lin M.  Role of intramolecular epitope spreading in pemphigus vulgaris.  Clin Immunol.  2005. 116(1):54-64.

Fairley J, Woodley D, Chen M, Giudice G, Lin M.  A patient with both bullous pemphigoid and epidermolysis bullosa acquisita: an example of intermolecular epitope spreading.  J Am Acad Dermatol.  2004. 51(1):118-22.
[PubMed]

Hacker-Foegen M, Salato V, Olasz E, Fairley J, Lazarova Z.  Analysis of autoimmune T cell repertoire in an active pemphigus vulgaris animal model.  J Invest Dermatol.  2004. 124:A6 (032A).

Colbert R, Allen D, Fairley J.  Mortality rate of bullous pemphigoid in a US medical center.  J Invest Dermatol.  2004. 122(5):1091-5.
[PubMed]

Reed K, Melski J, Graham M, Regnery R, Sotir M, Wegner M, Kazmierczak J, Stratman E, Fairley J, Li Y, Swain G, Olson V, Sargent E, Kehl S, Frace M, Kline R, Foldy S, Davis J, Damon I.  The detection of monkeypox in humans in the Western Hemisphere.  N Engl J Med.  2004. 350(4):342-50.
[PubMed]

Salato V, Foegen M, Lazarova Z, Fairley J, Lin M.  The role of intra-molecular epitope spreading in pemphigus vulgaris.  J Invest Dermatol.  2004. 122(3):A6 (031).

Melski M, Reed K, Stratman E, Graham M, Fairley J, Edmiston C, Kehl S, Foldy S, Swain G, Bierdrzcki P, Gieryn D, Ernst K, Schier D, Tomasello C, Rausch D, Healy-Haney N, Kreuser N, Wegner M, Kazmierczak J, Williams C, Croft D, Bostrom J, Davis J, Ehlenfeldt R, Kirk C, Teclaw R, Messersmith H, Sotir M, Huhn G, Fleischauer A.  Multistate outbreak of monkeypox--Illinois, Indiana, and Wisconsin, 2003.  MMWR Morb Mortal Wkly Rep.  2003 June. 13(52(23)):537-40.
[Link]

Hacker M, Olasz E, Fairley J, Yancey K, Lin M.  Anti-idiotypic IgG blocks the reactivity and pathogenicity of anti-desmoglein-3 autoantibodies from patients with pemphigus vulgaris.  J Invest Dermatol.  2003. 121(1):0080A.

Fu C, Giudice G, Fairley J.  Bullous pemphigoid IgE and IgG react with BP180 outside of the immunodominant NC16A domain.  J Invest Dermatol.  2003. 121(1):0094A.

Fairley J.  Calcifying and ossifying disorders.  Jean L. Bolognia, Joseph L. Jorizzo, Ronald P. Rapini, Thomas D Horn, Anthony J. Mancini, Jose M. Mascaro, Stuart J. Salasche, Jean-Hilaire Saurat, Georg Stingl.  2003. 1(8th):691-726.

Hacker M, Janson M, Fairley J, Lin M.  Epitopes and pathogenic activity of anti-desmoglein-1 in a subset of pemphigus foliaceus patients expressing only IgG1 autoantibodies.  J Invest Dermatol.  2003. 121(1):0040A.

Miller J, Giudice G, Janson M, Fairley J.  Fiberoptic confocal imaging of the skin.  J Invest Dermatol.  2003. 1(0094A).

Dimson O, Giudice G, Fu C, Van den Bergh F, Warren S, Janson M, Fairley J.  Identification of a potential effector function for IgE autoantibodies in the organ-specific autoimmune disease bullous pemphigoid.  J Invest Dermatol.  2003. 120(5):784-8.
[PubMed]

Gunkel J, Graham M, Fairley J.  Monkeypox.  EMedicine;  2003.  Available from: http://emedicine.medscape.com/article/1134714-overview

Woodley D, Krueger G, Jorgensen C, Fairley J, Atha T, Huang Y, Chan L, Keene D, Chen M.  Normal and gene-corrected dystrophic epidermolysis bullosa fibroblasts alone can produce type VII collagen at the basement membrane zone.  J Invest Dermatol.  2003. 121(5):1021-8.
[PubMed]

Hacker-Foegen M, Janson M, Amagai M, Fairley J, Lin M.  Pathogenicity and epitope characteristics of anti-desmoglein-1 from pemphigus foliaceus patients expressing only IgG1 autoantibodies.  J Invest Dermatol.  2003. 121(6):1373-6.
[PubMed]

Hacker M, Fairley J, Lin M.  T cell receptor gene usage in desmoglein-3 specific T-lymphocytes from patients with pemphigus vulgaris.  J Invest Dermatol.  2003. 121(1):0852A.

Hacker-Foegen M, Fairley J, Lin M.  T cell receptor gene usage in desmoglein-3-specific T lymphocytes from patients with pemphigus vulgaris.  J Invest Dermatol.  2003. 121(6):1365-72.
[PubMed]

Lyon V, Fairley J.  Anticonvulsant-induced pellagra.  J Am Acad Dermatol.  2002. 46(4):597-9.
[PubMed]

Lin M, Fu C, Olague-Marchan M, Hacker M, Zillikens D, Giudice G, Fairley J.  Autoimmune responses in patients with linear IgA bullous dermatosis: Both autoantibodies and T lymphocytes recognize the NC16A domain of the BP180 molecule.  Clin Immunol.  2002. 102(3):310-9.
[PubMed]

Fairley J, Dimson I, Fu C, Janson M, Giudice G.  BP180 specific IgE in bullous pemphigoid.  J Invest Dermatol.  2002. 119:607A.

Suchniak J, Diaz L, Lin M, Fairley J.  IgM mediated epidermolysis bullosa acquisita.  Arch Derm.  2002. 138(10):1385-6.
[PubMed]

Hacker M, Janson M, Fairley J, Lin M.  Isotypes and antigenic profiles of pemphigus foliaceus and pemphigus vulgaris autoantibodies.  Clin Immunology.  2002. 105(1):64-74.
[PubMed]

Hacker M, Janson M, Fairley J, Lin M.  Isotypes and antigenic profiles of pemphigus foliaceus and pemphigus vulgaris autoantibodies.  J Invest Dermatol.  2002. 119:538A.

Chen R, Fairley J, Zhao M, Giudice G, Zillikens D, Diaz L, Liu Z.  Macrophages, but not T and B lymphocytes are critical for subepidermal blister formation in experimental bullous pemphigoid: macrophage-mediated neutrophil infiltration depends on mast cell activation.  J Immunol.  2002. 169(7):3987-92.
[PubMed]

Chen M, O'Toole E, Sanghavi J, Mahmud N, Kelleher D, Weir D, Fairley J, Woodley D.  The epidermolysis bullosa acquisita antigen (type VII collagen) is present in human colon and patients with Crohn's disease have autoantibodies to type VII collagen.  J Invest Dermatol.  2002. 118(6):1059-64.
[PubMed]

Galbraith S, Fairley J, Esterly N.  White papules in a child with Down syndrome.  Ped Dermatol.  2002. 19(3):271-3.
[PubMed]

Woodley D, Chen M, Krueger K, Jorgensen C, Chan L, Fairley J.  Dermal fibroblasts alone are capable ofproducing type VII (anchoring fibril) collagen at the dermal-epidermal junction.  J Invest Dermatol.  2001. 119:399A.

Dimson O, Fu C, Janson M, Giudice G, Fairley J.  Detection of BP180 specific IgE antibodies in bullous pemphigoid and identification of a potential effector function.  J Invest Dermatol.  2001. 117:461A.

Fairley J, Zivony D.  Epidermal kinetics and regulation of cell proliferation.  The Parthenon Press Group Inc.  2001. 

Beaird L, Kahloon N, Franco J, Fairley J.  Incidence of hepatitis C with lichen planus.  J Am Acad Dermatol.  2001. 44(2):311-2.
[PubMed]

Gharia M, Fairley J, Lin M, Liu Z, Giudice G, Diaz L.  Autoimmune diseases of the skin.  Lippincott Williams & Wilkins.  2000 May 28. 

Liu Z, Shapiro S, Zhou X, twining S, Senior R, Giudice G, Fairley J, Diaz L.  A critical role for neutrophil elastase in experimental bullous pemphigoid.  J Clin Invest.  2000. 105(1):113-23.
[PubMed]

Chen M, Krueger G, Jorgensen C, Chan L, Fairley J, Woodley D.  Dermal fibroblasts alone are capable of producing type VII (anchoring fibril) collagen at the dermal-epidermal junction.  J Invest Dermatol.  2000. 

Fairley J, Suchniak J, Paller A.  Hedgehog hives.  Arch Derm.  1999. 135(5):561-3.
[PubMed]

Ding X, Diaz L, Fairley J, Giudice G, Liu Z.  The anti-desmoglein 1 autoantibodies in pemphigus vulgaris sera are pathogenic.  J Invest Dermatol.  1999. 112(5):739-43.
[PubMed]

Liu Z, Zhou X, Ding X, Chen R, Shapiro S, Senior R, Giudice G, Fairley J, Diaz L.  The role of neutrophil elastase, gelatinase B and plasmin/plasminogen activators in pemphigus foliaceus and pemphigus vulgaris in mice.  J Invest Dermatol.  1999. 112:562.

Fairley J, Pomeranz A.  A bullous pemphigoid-like skin eruption following a chemical burn.  J Am Acad Derm.  1998. 38(2 PT2):337-40.
[PubMed]

Lin M, Swartz S, Gharia M, Fairley J, Diaz L.  Autoimmune responses of linear IgA disease: both T cells and autoantibodies recognize NC16a domain of BP180.  J Invest Dermatol.  1998. 110:482.

Baselga E, Fairley J.  Calcifying and ossifying disorders in children.  Oxford University Press, London.  1998. 

McCord M, Fairley J.  Dermatology.  Willliam and Wilkins, New York, NY.  1998. 

Chan L, Vanderlugt C, Hashimoto T, Nishikawa T, Zone J, Black M, Wojnarowska F, Stevens S, Chen M, Fairley J, Woodley D, Miller S, Gordon K.  Epitope spreading: lessons from autoimmune skin diseases.  J Invest Dermatol.  1998. 110(2):103-9.
[PubMed]

Warren K, Fairley J.  Pain and swelling along the nail fold of a 51-year-old man.  Dermatol Online J;  1998. 

Fairley J, Ding X, Giudice G, Diaz L.  Pemphigus foliaceus and pemphigus vulgaris.  Humana Press, Totowa, NJ.  1998. 

Warren K, Fairley J.  Stump the experts. Subungual exostosis.  Dermatol Surg.  1998. 24(2):287-9.
[PubMed]

Pomeranz A, Fairley J.  Systematic evaluation of the skin of children.  Ped Clin North Am.  1998. 45(1):49-63.
[PubMed]

Gharia M, Swartz S, Giudice G, Fairley J, Diaz L, Lin M.  T cells from a mother with herpes gestationis, but not the newborn, specifically respond to BP180.  J Invest Dermatol.  1998. 110:507.

Ding X, Diaz L, Fairley J, Giudice G, Liu Z.  The anti-desmoglein autoantibodies in PV sera are pathogenic.  J Invest Dermatol.  1998. 110:507.

Liu Z, Giudice G, Zhou X, Swartz S, Troy J, Fairley J, Till G, Diaz L.  A major role for neutrophils in experimental bullous pemphigoid.  J Invest Dermatol.  1997. 100(5):1256-63.
[PubMed]

Caux F, Giudice G, Diaz L, Fairley J.  Autoimmune subepithelial blistering diseases with ocular involvement.  Immunol Allergy Clin.  1997. 17(1):139-59.
[Link]

Lin M, Swartz S, Lopez A, Ding X, Fairley J, Diaz L.  Characterization of desmoglein-1 epitopes recognized by T cells from patients with fogo selvagem.  J Invest Dermatol.  1997. 108:544A.

Lin M, Swartz S, Lopez A, Ding X, Fernandez-Vina M, Fairley J, Diaz L.  Development and characterization of desmoglein-3 specific T cells from patients with pemphigus vulgaris.  J Clin Invest.  1997. 99(1):31-40.
[PubMed]

Lin M, Swartz S, Lopez A, Ding X, Fairley J, Diaz L.  Development of Dsg-1 specific long term B cell lines from patients with pemphigus foliaceus.  J Invest Dermatol.  1997. 108:560A.

Wang J, Kwon J, Ding X, Fairley J, Woodley D, Diaz L.  IgA pemphigus is mediated by a non-secretory IgA1 autoantibody targeting desmoglein 3.  J Invest Dermatol.  1997. 108:638A.

Liu Z, Giudice G, Zhou X, Fairley J, Diaz L.  Interleukin-1 and-6 are required for subepidermal blistering in experimental bullous pemphigoid..  J Invest Dermatol.  1997. 108:538A.

Espana A, Diaz L, Mascaro Jr J, Giudice G, Fairley J, Till G, Liu Z.  Mechanisms of acantholysis in pemphigus foliaceus.  Clin Immunol Immunopath.  1997. 85(1):83-9.
[PubMed]

Mascaro Jr J, Espana A, Liu Z, Ding X, Swartz S, Fairley J, Diaz L.  Mechanisms of acantholysis in pemphigus vulgaris: Role of IgG valence.  J Immunol Immunopath.  1997. 85(1):90-6.
[PubMed]

Ding X, Aoki V, Mascaro J, Lopez-Swiderski A, Diaz L, Fairley J.  Mucosal and mucocutaneous (generalized) pemphigus vulgaris show distinct autoantibody profiles.  J Invest Dermatol .  1997. 109(4):592-6.
[PubMed]

Liu Z, Twining S, Giudice G, Zhou X, Fairley J, Diaz L.  Neutrophil elastase is essential for subepidermal blistering in experimental bullous pemphigoid.  J Invest Dermatol.  1997. 108:556A.

Wang J, Kwon J, Ding X, Fairley J, Woodley D, Chan L.  Nonsecretory IgA1 autoantibodies targeting a desmosomal component desmoglein 3 in intraepidermal neutrophilic IgA dermatosis.  Am J Path.  1997. 150(6):1901-7.
[PubMed]

Lin M, Swartz S, Lopez A, Ding X, Fairley J, Diaz L.  T lymphocytes from a subset of patients with pemphigus vulgaris respond to both desmoglein-3 and desmoglein-1.  J Invest Dermatol.  1997. 109(6):734-7.
[PubMed]

Miller E, Fairley J, Neuburg M.  Vulvar basal cell carcinoma.  Dermatol Surg.  1997. 23(3):207-9.
[PubMed]

Mascaro Jr J, Fairley J, Giudice G, Diaz L.  Autoantibodies in paraneoplastic pemphigus.  Elsevier, The Netherlands.  1996. 

Liu Z, Giudice G, Swartz S, Zillikens D, Troy J, Fairley J, Diaz L.  Bullous pemphigoid mouse model: dermal-epidermal separation induced by anti-BP180 antibodies is dependent on neutrophil Fc receptor activity.  J Invest Dermatol.  1996. 106:801A.

Liu Z, Twining S, Giudice G, Zhou X, Fairley J, Troy J, Diaz L.  Bullous pemphigoid mouse model: neutrophil elastase plays a major role in subepidermal blister formation.  J Invest Med.  1996. 44:402A.

Walsh J, Fairley J.  Calciphylaxis.  J Amer Acad Dermatol.  1996. 35(5):786-7.
[PubMed]

Fairley J.  Cicatricial pemphigoid.  J Geria Dermatol.  1996. 4:42-46.

Lin M, Swartz S, Lopez A, Fairley J, Diaz L.  Development and characterization of desmoglein-3 specific T-lymphocytes.  FASEB J.  1996. 10:A1305.

Lin M, Lopez A, Fairley J, Diaz L.  Development and characterization of T cell lines responding to desmoglein-3.  J Invest Dermatol.  1996. 106:832A.

Liu Z, Twinning S, Giudice G, Zhou X, Fairley J, Troy J, Diaz L.  Elastase plays a direct role in blister formation in experimental bullous pemphigoid.  FASB J.  1996. 10:A1407.

Kwon J, Wang J, Ding X, Fairley J, Woodley D, Chan L.  IgA pemphigus vulgaris is mediated by a non-secretory IgA1 autoantibody targeting desmoglein 3.  J Invest Med.  1996. 44:402A.

Ding X, Mascaro Jr J, Goldberg E, Fleming M, Diaz L, Fairley J.  IgG from a subset of PV patients with oral disease is not pathogenic in neonatal BALB/c mice.  J Invest Dermatol.  1996. 106:850A.

Mascaro Jr J, Espana-Alonso A, Liu Z, Swartz S, Fleming M, Giudice G, Fairley J, Diaz L.  Monovalent Fab fragments from pemphigus vulgaris IgG are pathogenic in neonatal BALB/c mouse model.  J Invest Dermatol.  1996. 106:812A.

Miller E, Esterly N, Fairley J.  Progressive osseous heteroplasia.  Arch Dermatol.  1996. 132(7):787-91.
[PubMed]

Diaz L, Espana-Alonso A, Fairley J, Giudice G, Mascaro Jr J, Liu Z.  Skin diseases autoantibodies.  Elsevier Science B.V., The Netherlands.  1996. 

Fairley J.  The role of adhesion molecules in autoimmune blistering diseases.  Rapid Science Publishers.  1996. 3:27-32.

Emery D, Diaz L, Fairley J, Lopez A, Taylor A, Giudice G.  Pemphigus foliaceus and pemphigus vulgaris autoantibodies react with the extracellular domain of desmoglein-1.  J Invest Dermatol.  1995 March. 104(3):323-8.
[PubMed]

Hans-Filho G, dos Santos V, Katayama J, Aoki V, Rivitti E, Sampaio S, Friedman H, Moraes J, Moraes M, Eaton D, Lopez A, Hoffman R, Fairley J, Giudice G, Diaz L.  An active focus of high prevalence of fogo selvagem on a Amerindian reservation in Brazil.  J Invest Dermatol .  1995. 107(1):68-75.
[PubMed]

Liu Z, Diaz L, Swartz S, Zillikens D, Troy J, Fairley J, Giudice G.  Bullous pemphigoid mouse model: dissection of the inflammatory response.  J invest Dermatol.  1995. 104:558.

Walsh J, Fairley J.  Calcifying disorders of the skin.  J Amer Acad Derm.  1995. 33(5 Pt 1):693-706 quiz 707-10.
[PubMed]

Troy J, Liu Z, Fairley J, Diaz L, Giudice G.  Dissection of the skins inflammatory response in experimentally induced pemphigoid.  J Cutan Pathol.  1995. 22:93A.

Fairley J, Heintz P, Neuburg M, Diaz L, Giudice G.  Expression pattern of the bullous pemphigoid-180 antigen in normal and neoplastic epithelia.  Br J Dermatol.  1995. 133(3):385-91.
[PubMed]

Ding X, Aoki V, Fleming M, Diaz L, Fairley J.  Heterogeneity of pemphigus vulgaris autoantibodies.  J Invest Dermatol.  1995. 105:872A.

Muramatsu T, Putzer K, Diaz L, Giudice G, Fairley J.  Identification of a conserved calcium binding site on the intracellular domain of cadherins.  J Invest Dermatol.  1995. 104:557.

Liu Z, Diaz L, Swartz S, Fairley J, Giudice G.  Molecular mapping of a BP180 peptide that can block subepidermal blistering in experimental bullous pemphigoid.  J Invest Dermatol.  1995. 104:559.

Liuz Z, Diaz L, Swartz S, Troy J, Fairley J, Giudice G.  Molecular mapping of a pathogenically relevant BP180 epitope associated with experimentally induced murine bullous pemphigoid.  J Immunol.  1995. 155(11):5449-54.
[PubMed]

Hansen K, Troy J, Fairley J.  Multiple papules of the scalp and forehead. Steatocystoma multiplex (facial papular variant).  Arch Dermatol.  1995. 131(7):835.
[PubMed]

Liuz Z, Giudice G, Swartz S, Fairley J, Till G, Troy J, Diaz L.  The role of complement in experimental bullous pemphigoid.  J Clin Invest.  1995. 95(4):1539-44.
[PubMed]

Espana A, Diaz L, Giudice G, Fairley J, Till G, Liu Z.  The role of complement in experimental pemphigus foliaceus.  J Invest Dermatol.  1995. 105:872A.

Liu Z, Diaz L, Schwartz S, Troy J, Taylor A, Emery D, Fairley J, Giudice G.  Bullous pemphigoid mouse model: a time course study of the inflammatory response during subepidermal blister formation.  Clin Res.  1994. 42:429A.

Liu Z, Diaz L, Swartz S, Taylor A, Emery D, Troy J, Fairley J, Giudice G.  Defining the animal model of bullous pemphigoid and herpes gestationis by passive transfer of anti-BP180 antibodies.  J Invest Dermatol.  1994. 102:558A.

Giudice G, Wilske K, Anhalt G, Fairley J, Taylor A, Emery D, Hoffman R, Diaz L.  Development of an ELISA to detect anti-BP180 autoantibodies in the sera of bullous pemphigoid and herpes gestationis patients.  J Invest Dermatol.  1994. 102(6):878-81.
[PubMed]

Scott G, Fairley J, Liang H, Giudice G.  Human melanocytes express the BP180 antigen in vitro.  J Invest Dermatol.  1994. 102:551A.

Aoki V, Diaz L, Taylor A, Witman P, Fairley J.  Immunological specificity of pemphigus vulgaris autoantibodies.  J Invest Dermatol.  1994. 102:564A.

Pomeranz A, Fairley J.  Management errors leading to unnecessary hospitalization for kerion.  Pediatrics.  1994. 93(6 Pt 1):986-8.
[PubMed]

Muramatsu T, Putzer K, Diaz L, Giudice G, Fairley J.  Mapping the extra- and intracellular calcium binding sites on the pemphigus vulgaris antigen (desmoglein 3).  J Invest Dermatol.  1994. 102:563A.

Giudice G, Emery D, Liu Z, Fairley J, Diaz L.  A bullous pemphigoid and herpes gestationis reactive site on the ectodomain of the human BP180 autoantigen is not present on the murine BP180 homologue.  Clin Res.  1993. 41:409A.

Liu Z, Diaz L, Troy J, Taylor A, Emery D, Fairley J, Giudice G.  A passive transfer model of the organ-specific autoimmune disease, bullous pemphigoid, using antibodies generated against the hemidesmosomal antigen, BP180.  J Clin Invest.  1993. 92(5):2480-88.
[PubMed]

Mansilla-Orihuela C, Diaz L, Taylor A, Emery D, Fairley J, Giudice G.  Bullous pemphigoid autoantibodies directed against a dominant epitope of the BP180 ectodomain are predominantly of the IgG2 subclass.  Clin Res.  1993. 

Hertz P, Giudice G, Diaz L, Fairley J.  Distribution of the bullous pemphigoid-180 autoantigen in normal and transformed tissue.  Clin Res.  1993. 41:410A.

Muramatsu T, Putzer K, Diaz L, Giudice G, Fairley J.  Identification of calcium binding sites on the pemphigus vulgaris antigen by 45calcium over.  Clin Res.  1993. 

Aoki V, Diaz L, Taylor A, Fairley J.  Pemphigus vulgaris autoantibodies: IgG subclass analysis utilizing immunofluorescence and immunoblotting.  Clin Res.  1993. 41:663A.

Liu Z, Diaz L, Taylor A, Emery D, Giudice G, Fairley J.  Studies on the human and murine bullous pemphigoid 180 (BP180) antigen.  Clin Res.  1993. 

Fairley J.  Tretinoin (retinoic acid) revisited.  N Engl J Med.  1993. 20(328(20)):1486-7.
[PubMed]

Fairley J, Arrindell S.  Calcium regulation of epidermal cell physiology.  Elsevier Inc.  1992. 

Fairley J, Putzer K, Giudice G.  Keratinocyte proliferation: correlation with calmodulin gene expression.  J Invest Dermatol.  1992. 98:640.

Scheinman P, Helm K, Fairley J.  Acral necrosis in a patient with chronic renal failure.  Arch Dermatol.  1991. 127(2):248-9.
[PubMed]

Fairley J.  Calcium metabolism and the pathogenesis of dermatologic disease.  Semin Dermatol.  1991. 10(3):225-31.
[PubMed]

Fairley J.  Calcium: A second messenger.  Oxford University Press, New York, NY.  1991. 2nd.

Fairley J, Putzer K, Giudice G.  Calmodulin gene expression in vivo and in vitro.  Clin Res.  1991. 39:719A.

Fairley J, Scott K, Jensen K, Goldsmith L, Diaz L.  Characterization of keratocalmin, a calmodulin-binding protein from human epidermis.  J Clin Invest.  1991. 88(1):315-22.
[PubMed]

Fairley J, Putzer K, Emery D, Giudice G.  Expression of calmodulin genes by keratinocytes in vitro and in vivo.  Clin Res.  1991. 39:458A.

Fairley J, Fung P, Ewing N.  Effect of ciclosporin A on epidermal keratinocytes in vitro: lack of a direct effect on calmodulin.  Skin Pharmacol.  1990. 3(3):149-56.
[PubMed]

Fairley J, Ghaneian M, Diaz L.  Identification and characterization of keratocalmin in keratinocytes in vitro.  Clin Res.  1990. 38:858A.

Fairley J, Scott G, Jensen K, Goldsmith L, Diaz L.  Identification of a human desmosome calmodulin-binding protein.  Clin Res.  1990. 38:610A.

Fairley J.  Intracellular receptors for cyclosporine A.  J Amer Acad Dermatol.  1990. 23(6 Pt 2):1329-32.
[PubMed]

Fairley J.  A Second Messenger.  Year Book Medical Publishers, Inc .  1989. 4:95-112.

Fairley J.  Calcium and the skin.  Arch Dermatol.  1989. 124(3):443-4.
[PubMed]

Fairley J, Fung P, Ewing N.  Calmodulin content of keratinocytes in vitro, effect of proliferation and cyclosporin A.  Clin Res.  1989. 37:633A.

Milstone L, Fairley J, Insogna K, Stewart A, Reuveni H, Schwartz P.  Parathyroid hormone-like peptides increase intracellular calcium and differentiation of keratinocytes.  Clin Res.  1989. 37:637A.

Milstone L, Fairley J, Insogna K, Stewart A, Reuveni H.  Parathyroid hormone-like peptides increase intracellular calcium and differentiation of keratinocytes.  J Cell Biol.  1989. 107:73A.

Fairley J, Sawyer J, Ewing N.  Characterization of epidermal calmodulin-binding proteins.  Clin Res.  1988. 36:375A.

Silverman A, Fairley J, Wong R.  Cutaneous and immunologic reactions to phenytoin.  J Amer Acad Dermatol.  1988. 18(4):721-41.

Fairley J, Ewing N, Keng P.  Extracellular calcium-induced terminal differentiation of keratinocytes is accompanied by an increase in free intracellular calcium.  Clin Res.  1988. 36:643A.

Fairley J, Ewing N, Keng P.  Retinoic acid decreases the free intracellular calcium level of keratinocytes.  Clin Res (J Invest Dermatol).  1987. 88(4):488.

Fairley J, Keng P.  Detection of changes in free intracellular Ca++ in keratinocytes using Indo-1 AM and flow cytometry.  Clin Res.  1986. 34:748A.

Fairley J, Keng P.  Detection of changes in free intracellular Ca++ in keratinocytes using Indo-1 AM and flow cytometry.  Clin Res.  1986. 334:748A.

Negi M, Lane A, McCoon P, Fairley J, Goldsmith L.  Monoclonal antibody to a 35 kD epidermal protein induces cell detachment.  J Invest Dermatol.  1986. 86(6):634-7.
[PubMed]

Fairley J, Ewing N, Keng P.  Retinoic acid decreases the free intracellular calcium level of keratinocytes.  Clin Res.  1986. 34:885A.

Fairley J, Ewing N, Keng P.  Retinoic acid decreases the free intracellular calcium level of keratinocytes.  Clin Res.  1986. 34:885A.

Fairley J, Marcelo C, Hogan V, Voorhees J.  Increased calmodulin levels in psoriasis and low Ca++ regulated mouse epidermal keratinocyte cultures.  J Invest Dermatol.  1985 March. 84(3):195-98.
[PubMed]

Soong H, Fairley J.  Actin in human corneal epithelium.  Arch Ophthalmol.  1985. 103(4):565-8.
[PubMed]

Soong H, Fairley J.  Actin in human corneal epithelium.  Association for Research in Vision and Ophthalmology.  1985. 

Fairley J, Marcelo C, Hogan V, Voorhees J.  Increased prostaglandin synthesis by low calcium regulated keratinocytes.  J Invest Dermatol.  1985. 86(3):195-8.
[PubMed]

Marcelo C, Hogan V, Fairley J.  Pemphigus vegetans limited to the oral mucosa.  Arch Dermatol.  1985. 121(2):271-2.
[PubMed]

Fairley J, Duell E, Hogan V, Marcelo C.  Production of arachidonic acid metabolites by low calcium regulated keratinocytes.  J Invest Dermatol.  1985. 84(365A).

LaRouere J, Fairley J, Grekin R, Marcelo C.  Calmodulin levels in skin tumors.  Clin Res.  1984. 32:597A.

Wong R, Ellis C, Fairley J.  Dermatographism: a review.  J Amer Acad Dermatol.  1984. 11(4 Pt 1):643-652.
[PubMed]

Marcelo C, Gold R, Fairley J.  Effect of 1.2mM calcium, triamcinolone acetonide, and retinoids on low-calcium regulated keratinocyte differentiation.  Br Dermatol.  1984. 111(27):64-72.
[PubMed]

Fairley J, Weiss J, Madison K, Marcelo C.  Increased prostaglandin synthesis by low calcium regulated keratinocytes.  Clin Res.  1984. 32:817A.

Fairley J, Hogan V, Marcelo C.  Localization of calmodulin in the epidermis.  Clin Res.  1984. 32:582A.

Madison K, Fairley J, Marcelo C, Voorhees J.  Prostaglandin production by hyperproliferative keratinocyte cultures: Effect of themitogens 8-Bromocyclic AMP and TPA.  Clin Res.  1984. 32:818A.

Fairley J, Pentland A, Voorhees J.  Urticaria pigmentosa responsive to nifedipine.  J Amer Acad Dermatol.  1984. 11(4 Pt 2):740-3.
[PubMed]

Fairley J, Rasmussen J.  Comparison of stratum corneum thickness in children and adults.  J Amer Acad Dermatol.  1983. 8(5):652-4.
[PubMed]

King A, Fairley J, Rasmussen J.  Disseminated cutaneous mycobacteriamarinum infection.  Arch Dermatol.  1983. 119(3):268-70.
[PubMed]

Marcelo C, Gold R, Fairley J.  Effect of triamcinalone acetonide, retinoids and 1.2mm Ca++ on low calcium (0.01mM) regulated keratinocyte differentiation.  CIRD, Valbonne, France.  1983. 

Fairley J, Hogan V, Marcelo C.  Epidermal keratinocyte calmodulin: Shifts in hyperproliferative systems.  Clin Res.  1983. 31:565A.

Fairley J, Marcelo C.  Activity of the de novo and salvage pathways of nucleotide synthesis.  Clin Res.  1982. 30:810A.

Fairley J, Tong P, Duell E.  Effect of 8-BrcAMP on epidermal cell protein phosphorylation.  Clin Res.  1982. 30:58A.

Fairley J, Dubin H.  Collagen vascular disease.  Perspec Ophthal.  1979. 3:203-211.

Heimbach L, Zhao M, Li N, Fan J, Fairley J, Diaz L, liu z.  TNF-α is critical for the autoimmune skin blistering disease bullous pemphigoid.  J immunol. 

Date Last Modified: 09/18/2014 - 15:48:21